140 related articles for article (PubMed ID: 20636371)
1. Neuropsychiatric symptoms and brain structural alterations in Fabry disease.
Schermuly I; Müller MJ; Müller KM; Albrecht J; Keller I; Yakushev I; Beck M; Fellgiebel A
Eur J Neurol; 2011 Feb; 18(2):347-353. PubMed ID: 20636371
[TBL] [Abstract][Full Text] [Related]
2. Eight-Year Follow-Up of Neuropsychiatric Symptoms and Brain Structural Changes in Fabry Disease.
Lelieveld IM; Böttcher A; Hennermann JB; Beck M; Fellgiebel A
PLoS One; 2015; 10(9):e0137603. PubMed ID: 26340726
[TBL] [Abstract][Full Text] [Related]
3. Hippocampal atrophy as a surrogate of neuronal involvement in Fabry disease.
Fellgiebel A; Wolf DO; Kolodny E; Müller MJ
J Inherit Metab Dis; 2012 Mar; 35(2):363-7. PubMed ID: 21932096
[TBL] [Abstract][Full Text] [Related]
4. Pattern of microstructural brain tissue alterations in Fabry disease: a diffusion-tensor imaging study.
Fellgiebel A; Mazanek M; Whybra C; Beck M; Hartung R; Müller KM; Scheurich A; Dellani PR; Stoeter P; Müller MJ
J Neurol; 2006 Jun; 253(6):780-7. PubMed ID: 16511647
[TBL] [Abstract][Full Text] [Related]
5. Cognitive functioning and depressive symptoms in Fabry disease: A follow-up study.
Körver S; Geurtsen GJ; Hollak CEM; van Schaik IN; Longo MGF; Lima MR; Dijkgraaf MGW; Langeveld M
J Inherit Metab Dis; 2020 Sep; 43(5):1070-1081. PubMed ID: 32510623
[TBL] [Abstract][Full Text] [Related]
6. Cognitive dysfunction and white matter hyperintensities in Fabry disease.
Murphy P; Williams F; Davagnanam I; Chan E; Murphy E; Hughes D; Quattrocchi G; Werring DJ; Lachman RH; Cipolotti L
J Inherit Metab Dis; 2022 Jul; 45(4):782-795. PubMed ID: 34994980
[TBL] [Abstract][Full Text] [Related]
7. [Pathophysiological aspects of brain structural disturbances in patients with Fabry disease: literature review].
Nill M; Müller MJ; Beck M; Stoeter P; Fellgiebel A
Fortschr Neurol Psychiatr; 2006 Dec; 74(12):687-95. PubMed ID: 17167727
[TBL] [Abstract][Full Text] [Related]
8. Voxel based analyses of diffusion tensor imaging in Fabry disease.
Albrecht J; Dellani PR; Müller MJ; Schermuly I; Beck M; Stoeter P; Gerhard A; Fellgiebel A
J Neurol Neurosurg Psychiatry; 2007 Sep; 78(9):964-9. PubMed ID: 17449543
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic utility of different MRI and MR angiography measures in Fabry disease.
Fellgiebel A; Keller I; Marin D; Müller MJ; Schermuly I; Yakushev I; Albrecht J; Bellhäuser H; Kinateder M; Beck M; Stoeter P
Neurology; 2009 Jan; 72(1):63-8. PubMed ID: 19122032
[TBL] [Abstract][Full Text] [Related]
10. Diffuse structural and metabolic brain changes in Fabry disease.
Marino S; Borsini W; Buchner S; Mortilla M; Stromillo ML; Battaglini M; Giorgio A; Bramanti P; Federico A; De Stefano N
J Neurol; 2006 Apr; 253(4):434-40. PubMed ID: 16541218
[TBL] [Abstract][Full Text] [Related]
11. Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease.
Fellgiebel A; Gartenschläger M; Wildberger K; Scheurich A; Desnick RJ; Sims K
Cerebrovasc Dis; 2014; 38(6):448-56. PubMed ID: 25502511
[TBL] [Abstract][Full Text] [Related]
12. Patients with primary biliary cholangitis and fatigue present with depressive symptoms and selected cognitive deficits, but with normal attention performance and brain structure.
Zenouzi R; von der Gablentz J; Heldmann M; Göttlich M; Weiler-Normann C; Sebode M; Ehlken H; Hartl J; Fellbrich A; Siemonsen S; Schramm C; Münte TF; Lohse AW
PLoS One; 2018; 13(1):e0190005. PubMed ID: 29320524
[TBL] [Abstract][Full Text] [Related]
13. White matter integrity correlates with cognition and disease severity in Fabry disease.
Ulivi L; Kanber B; Prados F; Davagnanam I; Merwick A; Chan E; Williams F; Hughes D; Murphy E; Lachmann RH; Wheeler-Kingshott CAMG; Cipolotti L; Werring DJ
Brain; 2020 Dec; 143(11):3331-3342. PubMed ID: 33141169
[TBL] [Abstract][Full Text] [Related]
14. A long-term neuropsychological evaluation in Fabry disease.
Loret G; Miatton M; Vingerhoets G; Poppe B; Hemelsoet D
Acta Neurol Belg; 2021 Feb; 121(1):191-197. PubMed ID: 32915382
[TBL] [Abstract][Full Text] [Related]
15. Depressive symptoms in Fabry disease: the importance of coping, subjective health perception and pain.
Körver S; Geurtsen GJ; Hollak CEM; van Schaik IN; Longo MGF; Lima MR; Vedolin L; Dijkgraaf MGW; Langeveld M
Orphanet J Rare Dis; 2020 Jan; 15(1):28. PubMed ID: 31992347
[TBL] [Abstract][Full Text] [Related]
16. Cognitive dysfunction and depression in Fabry disease: a systematic review.
Bolsover FE; Murphy E; Cipolotti L; Werring DJ; Lachmann RH
J Inherit Metab Dis; 2014 Mar; 37(2):177-87. PubMed ID: 23949010
[TBL] [Abstract][Full Text] [Related]
17. Neurological complications of Anderson-Fabry disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Arnao V; Licata G; Pinto A
Curr Pharm Des; 2013; 19(33):6014-30. PubMed ID: 23448452
[TBL] [Abstract][Full Text] [Related]
18. Development and clinical consequences of white matter lesions in Fabry disease: a systematic review.
Körver S; Vergouwe M; Hollak CEM; van Schaik IN; Langeveld M
Mol Genet Metab; 2018 Nov; 125(3):205-216. PubMed ID: 30213639
[TBL] [Abstract][Full Text] [Related]
19. Quantification of brain tissue alterations in Fabry disease using diffusion-tensor imaging.
Fellgiebel A; Albrecht J; Dellani PR; Schermuly I; Stoeter P; Müller MJ
Acta Paediatr; 2007 Apr; 96(455):33-6. PubMed ID: 17391437
[TBL] [Abstract][Full Text] [Related]
20. Basilar artery diameter is a potential screening tool for Fabry disease in young stroke patients.
Fellgiebel A; Keller I; Martus P; Ropele S; Yakushev I; Böttcher T; Fazekas F; Rolfs A
Cerebrovasc Dis; 2011; 31(3):294-9. PubMed ID: 21196729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
